TABLE 1.
Demographics and baseline lipid-lowering therapy
| Placebo N = 11 | Mipomersen N = 10 | FHBL N = 6 | |
|---|---|---|---|
| Gender (M:F)a | 3:8 | 6:4 | 5:1 |
| Age | 46 (1)a | 49 (12)a | 49 (16)a |
| BMI | 26a | 27a | 30a |
| Statin (mg/day) | |||
| Atorvastatin | |||
| 20 | 1 (10)b | ||
| 40 | 1 (9)b | 2 (20)b | |
| 80 | 4 (36)b | 1 (10)b | |
| Rosuvastatin | |||
| 5 | 2 (18)b | ||
| 20 | 1 (9)b | 1 (10)b | |
| 40 | 2 (18)b | 4 (40)b | |
| Simvastatin | |||
| 80 | 1 (10)b | ||
| Pravastatin | |||
| 40 | 1 (9)b | ||
| Ezetemibe | |||
| 10 | 7 (64)b | 9 (90)b | |
| Other | 1 (9)b | 1 (10)b |
BMI, body mass index; F, female; FHBL, familial hypobetalipoproteinemia; M, male.
a
Values are the mean and (standard deviation).
b
Values are the number of subjects (and percentage) by drug type and dose.